CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


DipyridamoleWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients

Brief Summary: The goal here is to evaluate dipyridamole in treating respiratory tract infection and circulatory dysfunction due to SARS-CoV-2 coronavirus in hospitalized CVID-19 patients. Infection with SARS-CoV-2 causes human COVID-19 (HCoV-19). The infection is associated with a deleterious inflammatory response and a prothrombotic state in addition to tissue damage from direct viral entry and proliferation. Dipyridamole has anti-platelet and anti-inflammatory effects. The drug was recently demonstrated to have anti-SARS-Cov-2 effect primarily in vitro. The concentration causing anti-viral effect in vitro is within that in the blood of humans taking this drug. As an oral tablet, it has the advantage of easy administration. Anti thrombotic, anti viral and anti inflammatory actions of this drug may be efficacious and safe in hospitalized subjects

NCT04424901 COVID-19 Pneumonia Vascular Complications Drug: Dipyridamole
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: D-dimer and platelet count

Measure: Coagulation system

Time: 9 days

Secondary Outcomes

Description: Evaluate for a non-detection from nasopharyngeal swab and in stool

Measure: Viral Detection

Time: 9 days

Other Outcomes

Description: Survival Status Alive

Measure: Survival

Time: 9 days

Description: Change in the markers CRP/Ferritin

Measure: Inflammatory Markers

Time: 9 days

Description: Change in Lymphocyte Count/ Fibrinogen/Cardiac Troponin

Measure: Blood Markers

Time: 9 days

Description: Change in PT, PTT

Measure: Coagulation Markers

Time: 9 days

Description: Change in SpO2/ imaging

Measure: Pulmonary Status

Time: 9 days

Description: Change in fever, cough, sputum

Measure: Clinical Status

Time: 9 days


Related HPO nodes (Using clinical trials)